menu
    • menu
    [{"orgOrder":0,"company":"Fresenius Medical Care","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Dietary Supplement","year":"2012","type":"Inapplicable","leadProduct":"Glucose","moa":"Blood glucose level","graph1":"Nephrology","graph2":"Phase IV","graph3":"Fresenius Medical Care","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Fresenius Medical Care \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Medical Care \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Medical Care","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Protein","year":"2010","type":"Inapplicable","leadProduct":"ERYTHROPOIETIN","moa":"Erythropoietin receptor","graph1":"Nephrology","graph2":"Phase II","graph3":"Fresenius Medical Care","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Medical Care \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"Fresenius Medical Care \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Medical Care","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Calcium Acetate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase II\/ Phase III","graph3":"Fresenius Medical Care","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Granules","sponsorNew":"Fresenius Medical Care \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Fresenius Medical Care \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Medical Care","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Calcium Acetate","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase IV","graph3":"Fresenius Medical Care","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Fresenius Medical Care \/ Undisclosed","highestDevelopmentStatusID":"11","companyTruncated":"Fresenius Medical Care \/ Undisclosed"},{"orgOrder":0,"company":"Fresenius Medical Care","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Iron Sucrose","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase III","graph3":"Fresenius Medical Care","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Medical Care \/ Fresenius Medical Care","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Medical Care \/ Fresenius Medical Care"},{"orgOrder":0,"company":"Fresenius Medical Care","sponsor":"CSL Vifor","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"SWITZERLAND","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Iron Sucrose","moa":"Phosphate","graph1":"Nephrology","graph2":"Phase III","graph3":"Fresenius Medical Care","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Medical Care \/ Fresenius Medical Care","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Medical Care \/ Fresenius Medical Care"},{"orgOrder":0,"company":"Fresenius Medical Care","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Nephrology","country":"GERMANY","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"Dialysis","moa":"Undisclosed","graph1":"Nephrology","graph2":"Phase III","graph3":"Fresenius Medical Care","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Nephrology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Fresenius Medical Care \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Fresenius Medical Care \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Fresenius Medical Care

    Menu

    Fresenius Medical Care

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Fresenius Medical Care

                            Mexico arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Fresenius Medical Care

                            Mexico arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dialysis

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SAfety of Regional Citrate Anticoagulation (SARCA Study)

                            Details : Dialysis is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Acute Kidney Injury.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            April 21, 2022

                            Lead Product(s) : Dialysis

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Fresenius Medical Care

                            Mexico arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Fresenius Medical Care

                            Mexico arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Calcium Acetate

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Therapeutic Equivalence of OsvaRen® Tablets and OsvaRen® Granules

                            Details : Calcium Acetate is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Hyperphosphatemia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 06, 2014

                            Lead Product(s) : Calcium Acetate

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Fresenius Medical Care

                            Mexico arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Fresenius Medical Care

                            Mexico arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Glucose

                            Therapeutic Area : Nephrology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Effect of Balance PD Solution on the Peritoneal Membrane in Patients on Automated Peritoneal Dialysis

                            Details : Glucose is a Dietary Supplement drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Kidney Failure, Chronic.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            December 20, 2012

                            Lead Product(s) : Glucose

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Fresenius Medical Care

                            Mexico arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Fresenius Medical Care

                            Mexico arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iron Sucrose

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Recipient : CSL Vifor

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 3 Extension Study to Investigate the Long-term Safety, Tolerability and Efficacy of PA21, a Phosphate ...

                            Details : Sucroferric Oxyhydroxide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Renal Insufficiency, Chronic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 03, 2011

                            Lead Product(s) : Iron Sucrose

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Recipient : CSL Vifor

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Fresenius Medical Care

                            Mexico arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Fresenius Medical Care

                            Mexico arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Calcium Acetate

                            Therapeutic Area : Nephrology

                            Study Phase : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Equivalence of Calcium Acetate Oral Solution and Sevelamer Carbonate Tablets in Hemodialysis Patients

                            Details : Calcium Acetate is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Renal Insufficiency, Chronic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            September 02, 2011

                            Lead Product(s) : Calcium Acetate

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase IV

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Fresenius Medical Care

                            Mexico arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Fresenius Medical Care

                            Mexico arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Iron Sucrose

                            Therapeutic Area : Nephrology

                            Study Phase : Phase III

                            Recipient : CSL Vifor

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase 3 Study to Investigate the Safety and Efficacy of PA21, a Phosphate Binder, in Dialysis Patients

                            Details : Sucroferric Oxyhydroxide is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Renal Insufficiency, Chronic.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 28, 2011

                            Lead Product(s) : Iron Sucrose

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase III

                            Recipient : CSL Vifor

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Fresenius Medical Care

                            Mexico arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Fresenius Medical Care

                            Mexico arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Nephrology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Safety Study of Pentoxifylline for the Treatment of Anemia

                            Details : Erythropoietin is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Kidney Failure, Chronic.

                            Product Name : Undisclosed

                            Product Type : Protein

                            Upfront Cash : Inapplicable

                            April 13, 2010

                            Lead Product(s) : ERYTHROPOIETIN

                            Therapeutic Area : Nephrology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth